NASDAQ · Biotechnology · USD
Inhibikase Therapeutics, Inc. (IKT) Stock Analysis
Inhibikase Therapeutics, Inc. (IKT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
IKT Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.71
- Previous Close
- $1.71
- Day's Range
- 1.65–1.76
- 52-Week Range
- 1.33–2.61
- Volume
- 529.00K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.90
Valuation
- Market Cap
- $231.63M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.43
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$48.26M
- Shares Outstanding
- 139.54M
- 1-Year Return
- +5.06%
Dividend and dates
- Earnings Date
- November 13, 2026estimated
- Avg Volume
- 600.30K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, IKT closed at $1.66, +5.06% over 1 year.
Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $231.63M.
In fiscal 2025, IKT reported revenue of $0.00.
IKT Stock Return by Calendar Year
Inhibikase Therapeutics, Inc. (IKT) return since Dec 2020: what $10,000 became
- 1 year
- $10,000 $10,506
- +5.06%
- 5 years
- $10,000 $1,529
- −84.71%
- Since Dec 2020
- $10,000 $279
- −97.21%
If you had invested $10,000 in Inhibikase Therapeutics, Inc. (IKT) at the close on December 23, 2020, the earliest close on record here, it would have been worth $279 at the close on October 21, 2026: −97.21% in total, −45.88% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −19.02% |
| 2025 | −36.92% |
| 2024 | +155.91% |
| 2023 | −57.67% |
| 2022 | −65.99% |
| 2021 | −78.70% |
| 2020 (partial year) | −30.30% |
As of October 21, 2026.
IKT Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$48.26M | — |
| 2024 | $0.00 | −$27.52M | — |
| 2023 | $0.00 | −$19.03M | — |
| 2022 | $0.00 | −$18.05M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$53.35M | −$48.26M | — |
| 2024 | $0.00 | — | −$28.59M | −$27.52M | — |
| 2023 | $0.00 | — | −$20.09M | −$19.03M | — |
| 2022 | $0.00 | — | −$18.13M | −$18.05M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
YahooChardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5
BenzingaInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YahooInhibikase Therapeutics Q2 EPS $(0.11), Inline
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B